A biotech using AI to design new protein drugs, like a digital architect for molecules, targeting asthma and cancer with experimental therapies.
Money comes from tiny collaboration revenue (USD 0.03B annually), but losses dominate—net income is negative USD 0.20B, with gross margins high but overall margins deeply unprofitable.
Their AI platform and proprietary biohardware create technical barriers, but competitors like Recursion Pharmaceuticals and Exscientia are advancing similar generative biology approaches, making the moat eroding.
Key events, in time order
None yet
None yet
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
